Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: Compartment analysis for β-CFT binding with positron emission tomography

Annals of Neurology

Volumn 45, Issue 5, 1999, Pages 601-610

  Ouchi, Yasuomi ^a,d   Yoshikawa, Etuji ^b   Okada, Hiroyuki ^b   Futatsubashi, Masami ^b   Sekine, Yoshimoto ^c   Iyo, Masaomi ^c   Sakamoto, Masanobu ^d  

^a Positron Medical Center   (Japan)

^b Central Research Laboratory   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d HAMAMATSU MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; TROPANE DERIVATIVE;

ADULT; AGED; AMYGDALOID NUCLEUS; ARTICLE; BEHAVIOR DISORDER; BINDING KINETICS; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION FUNCTION; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MALE; MENTAL HEALTH; ORBITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; THINKING;

AGED; AMYGDALA; BINDING SITES; BRAIN; CARRIER PROTEINS; CEREBRAL CORTEX; COCAINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FRONTAL LOBE; HUMANS; KINETICS; MAGNETIC RESONANCE IMAGING; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; ORBIT; PARKINSON DISEASE; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032963916     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199905)45:5<601::AID-ANA8>3.0.CO;2-0     Document Type: Article

References (57)

1. Kuhar MJ, Sanchez-Roa PM, Wong DF, et al. Dopamine transporter: biochemistry, pharmacology and imaging. Eur Neurol 1990;30:15-20
2. Aquilonius SM, Bergstrom K, Eckernas SA, et al. In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography. Acta Neurol Scand 1987;76:283-287
3. Kilbourn MR. In vivo binding of [18F]GBR 13119 to the brain dopamine uptake system. Life Sci 1988;42:1347-1353
4. Fowler JS, Volkow ND, Wolf AP, et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 1989;4: 371-377
5. 11C]WIN 35,428. Synapse 1993;15:130-142
6. 11C-CFT. Exp Neurol 1994;126:305-309
7. 11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 1998;18:419-427
8. Laihinen AO, Rinne JO, Nagren KA, et al. PET studies on brain monoamine transporters with carbon-11-beta-CIT in Parkinson's disease. J Nucl Med 1995;36:1263-1267
9. 11C]beta-CFT in early Parkinson's disease. Synapse 1995;21:97-103
10. Gjedde A, Wong DF. Modeling neuroreceptor binding of radioligands in vivo. In: Frost JJ, Wagner HR Jr, eds. Quantitative imaging: neuroreceptors, neurotransmitters, and enzymes. New York: Raven Press, 1990:51-79
11. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598
12. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 1991;9:43-49
13. Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455
14. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880
15. Oades RD, Halliday GM. Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity. Brain Res 1987; 434:117-165
16. Braak H, Braak E, Yilmazer D, et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol Berl 1994;88:493-500
17. Hoehn MW, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology (Minneap) 1967;17:427-445
18. Fahn S, Elton RL. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Florham Park, NJ: MacMillan Healthcare Information, 1987:153-163
19. Wechsler D. The Wechsler adult intelligence scale-revised. San Antonio, TX: Psychological Corporation, 1981
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
21. Ouchi Y, Nobezawa S, Okada H, et al. Glucose metabolism of the human hippocampal formation in the hippocampal long axis plane measured by PET. J Cereb Blood Flow Metab 1997; 17:S218 (Abstract)
22. Yamashita T, Uchida H, Okada H, et al. Development of a high resolution PET. IEEE Trans Nucl Sci 1990;37:594-599
23. Hoffman E, Phelps M. Positron emission tomography: principles and quantification. In: Phelps M, Mazziotta JC, Schelbert HR, eds. Positron emission tomography and autoradiography: principles and applications for the brain and heart. New York: Raven Press, 1986:237-286
24. Mai JK, Assheuer J, Paxinos G. Atlas of the human brain. San Diego: Academic Press, 1997
25. Watson C, Andermann F, Gloor P, et al. Anatomic basis of amygdaloid and hippocampal volume measurement by magnetic resonance imaging. Neurology 1992;42:1743-1750
26. Buchanan RW, Vladar K, Barta PE, Pearlson GD. Structural evaluation of the prefrontal cortex in schizophrenia. Am J Psychiatry 1998;155:1049-1055
27. Backman L, Robins-Wahlin TB, Lundin A, et al. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 1997;120:2207-2217
28. Soininen HS, Partanen K, Pitkanen A, et al. Volumetric MRI analysis of the amygdala and the hippocampus in subjects with age-associated memory impairment: correlation to visual and verbal memory. Neurology 1994;44:1660-1668
29. Koeppe RA, Holthoff VA, Frey KA, et al. Compartmental analysis of [11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 1991;11:735-744
30. Palacios JM, Camps M, Cortes R, Probst A. Mapping dopamine receptors in the human brain. J Neural Transm Suppl 1988;27:227-235
31. Mintun MA, Raichle ME, Kilbourn MR, et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984;15:217-227
32. 18F]dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28:547-555
33. 18F-dopa and positron emission tomography. Neurology 1992;42:1894-1900
34. Cumming P, Gjedde A. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms. Synapse 1998;29:37-61
35. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431
36. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997;48:1578-1583
37. Rinne JO, Rummukainen J, Paljarvi L, Rinne UK. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989;26:47-50
38. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301
39. Porrino LJ, Goldman-Rakic PS. Brain stem innervation of prefrontal and anterior cingulate cortex in the rhesus monkey revealed by retrograde transport of HRP. J Comp Neurol 1982; 205:63-76
40. Oeth KM, Lewis DA. Cholecystokinin-and dopamine-containing mesencephalic neurons provide distinct projections to monkey prefrontal cortex. Neurosci Lett 1992;145:87-92
41. Scatton B, Rouquier L, Javoy-Agid F, Agid Y. Dopamine deficiency in the cerebral cortex in Parkinson disease. Neurology 1982;32:1039-1040
42. German DC, Manaye K, Smith WK, et al. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol 1989;26:507-514
43. Uhl GR, Hedreen JC, Price DL. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 1985;35:1215-1218
44. Churchyard A, Lees AJ. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 1997;49:1570-1576
45. Sarter M, Markowitsch HJ. The amygdala's role in human mnemonic processing. Cortex 1985;21:7-24
46. LaBar KS, Gatenby JC, Gore JC, et al. Human amygdala activation during conditioned fear acquisition and extinction: a mixed-trial fMRI study. Neuron 1998;20:937-945
47. Morris JS, Ohman A, Dolan RJ. Conscious and unconscious emotional learning in the human amygdala. Nature 1998;393: 467-470
48. Adolphs R, Tranel D, Damasio H, Damasio AR. Fear and the human amygdala. J Neurosci 1995;15:5879-5891
49. Phillips ML, Young AW, Senior C, et al. A specific neural substrate for perceiving facial expressions of disgust. Nature 1997; 389:495-498
50. Morris JS, Friston KJ, Buchel C, et al. A neuromodulatory role for the human amygdala in processing emotional facial expressions. Brain 1998;121:47-57
51. Jacobs DH, Shuren J, Bowers D, Heilman KM. Emotional facial imagery, perception, and expression in Parkinson's disease. Neurology 1995;45:1696-1702
52. 18F]fluorodopa positron emission tomographic studies. Mov Disord 1990;5:203-213
53. Ouchi Y, Nobezawa S, Okada H, et al. Altered glucose metabolism in the hippocampal head in memory impairment. Neurology 1998;51:136-142
54. 11C]beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology 1998;50:152-156
55. Torstenson R, Hartvig P, Langstrom B, et al. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann Neurol 1997;41:334-340
56. Bannon MJ, Poosch MS, Xia Y, et al. Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc Natl Acad Sci USA 1992;89:7095-7099
57. Carroll BJ, Feinberg M, Smouse PE, et al. The Carroll rating scale for depression, I. Development, reliability and validation. Br J Psychiatry 1981;138:194-200